Oct 17, 2023 / 12:30PM GMT
Jason A. Okazaki - Assembly Biosciences, Inc. - CEO, President & Director
Good morning. I'm Jason Okazaki, President and CEO of Assembly Bio, and I'm thrilled to welcome you to our webcast to discuss our announcement today of a long-term partnership with Gilead to advance and accelerate the discovery and development of novel antiviral therapies with the potential to address significant unmet medical needs in herpes viruses, hepatitis and beyond.
I'm here with Dr. Bill Delaney, our Chief Scientific Officer. And together, we'd like to provide more color and answer questions on what we believe to be a monumental alliance for Assembly Bio and a collaboration that will allow us to help patients globally with a tremendous partner.
But first, a few housekeeping items. To submit a question to the queue, you may enter it into the Q&A chat box below the video player at any time. (Operator Instructions)
Before we begin, I'd also like to remind you that we will be making forward-looking statements, so please refer to our SEC filings for a full list of disclosures. Also, today's
Assembly Biosciences Inc Partnership with Gilead Sciences Inc to Develop Next-Generation Antiviral Therapeutics Call Transcript
Oct 17, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers